Fluticasone furoate/vilanterol
Combination of | |
---|---|
Fluticasone furoate | Corticosteroid |
Vilanterol | Long-acting β2 agonist |
Names | |
Trade names | Breo Ellipta, Relvar Ellipta |
Clinical data | |
Main uses | COPD, asthma[1] |
Side effects | Thrush, headache, upper respiratory tract infection, cough, throat pain, pneumonia, bronchospasm, glaucoma, low potassium[1] |
Routes of use | Inhalation |
External links | |
AHFS/Drugs.com | breo-ellipta |
Legal | |
License data | |
Legal status |
Fluticasone furoate/vilanterol (FF/VI), sold under the brand name Breo Ellipta among others, is a combination medication used for long-term treatment of chronic obstructive pulmonary disease (COPD) and asthma.[1] In Europe it as a second-line therapy.[5] It is used by breathing it in through the mouth.[1]
Common side effects include thrush, headache, upper respiratory tract infection, cough, and throat pain.[1] Other side effects may include pneumonia, bronchospasm, glaucoma, and low potassium.[1] It contains fluticasone furoate, a corticosteroid, and vilanterol, a long-acting β2 agonist (LABA).[1] There are concerns that a LABA alone may worsen outcomes in asthma.[1]
The combination was approved for medical use in the United States and Europe in 2013.[1][4] It is on the World Health Organization's List of Essential Medicines as an alternative to budesonide/formoterol.[6] It is available as a generic medication.[7] In the United States it costs about 160 USD for 60 doses as of 2023.[7] The amount in the United Kingdom costs the NHS about £44.[8] In 2020, it was the 115th most commonly prescribed medication in the United States, with more than 5 million prescriptions.[9][10]
Medical uses
Dosage
It is used as one inhalation once per day.[4]
History
Approval
This drug was approved by the FDA for use as a long-term, once-daily, maintenance treatment in people with COPD in 2013. Labeling changed on 30 April 2015, to add an indication for a once-daily treatment of asthma in people 18 years or older.[1] The exclusivity for a new product ended in May 2016, in the United States, and the exclusivity on the indication for asthma expired on 30 April 2018.[11] The patent for both indications expires on 3 August 2021.[11] The European Medicines Agency approved the drug for marketing on 13 November 2013.[12]
Society and culture
Commercial information
GlaxoSmithKline manufactures this drug. As of 31 December 2015, FF/VI inhalation powder was approved for marketing in 73 countries, and had been launched in 45 countries.[13] Within the trade name, the "Ellipta" is the dry powder inhaler that the medication is administered in. Innoviva developed the active substance vilanterol, and receives royalties on sales.[14]
Research
There is tentative evidence as of 2016 that it is better than placebo for asthma.[15] Evidence is less strong in children.[15]
References
- 1 2 3 4 5 6 7 8 9 10 11 "Breo Ellipta- fluticasone furoate and vilanterol trifenatate powder". DailyMed. Archived from the original on 26 May 2020. Retrieved 23 March 2021.
- ↑ "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.
- ↑ "Relvar Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed - Summary of Product Characteristics (SmPC)". (emc). 7 December 2020. Archived from the original on 5 February 2020. Retrieved 23 March 2021.
- 1 2 3 "Relvar Ellipta EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 5 February 2020. Retrieved 23 March 2021.
- ↑ "Summary of opinion: Relvar Ellipta" (PDF). European Medicines Agency. 19 September 2013. Archived (PDF) from the original on 24 September 2015. Retrieved 28 May 2023.
- ↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
- 1 2 "Generic Breo Ellipta". GoodRx. Archived from the original on 25 April 2020. Retrieved 9 September 2023.
- ↑ "Fluticasone with vilanterol Medicinal forms". NICE. Archived from the original on 10 September 2023. Retrieved 9 September 2023.
- ↑ "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 7 October 2022.
- ↑ "Fluticasone; Vilanterol - Drug Usage Statistics". ClinCalc. Archived from the original on 10 October 2022. Retrieved 7 October 2022.
- 1 2 "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations". www.accessdata.fda.gov. Archived from the original on 21 November 2016. Retrieved 20 November 2016.
- ↑ "European Medicines Agency - Find medicine - Relvar Ellipta". EMA.Europa.eu. Archived from the original on 21 November 2016. Retrieved 20 November 2016.
- ↑ "Innoviva | Primed for Portfolio Growth". Inva.com. Archived from the original on 21 November 2016. Retrieved 20 November 2016.
- ↑ "Innoviva Reports Second Quarter 2016 Financial Results | Business Wire". BusinessWire.com. 28 July 2016. Archived from the original on 21 November 2016. Retrieved 20 November 2016.
- 1 2 Dwan K, Milan SJ, Bax L, Walters N, Powell C (September 2016). "Vilanterol and fluticasone furoate for asthma". The Cochrane Database of Systematic Reviews. 9 (9): CD010758. doi:10.1002/14651858.CD010758.pub2. PMC 6472525. PMID 27582089.
External links
Identifiers: |
---|
- "Fluticasone furoate mixture with vilanterol". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 2023-08-26. Retrieved 2023-05-28.